Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a dual energy catheter tame dangerous heart rhythms?

NCT ID NCT07727057

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Sep 01, 2026 · Updated 6 times

Summary

This trial investigates whether a new dual energy catheter system can safely and effectively treat ventricular arrhythmias—abnormal heart rhythms that can be life-threatening. The system uses both radiofrequency and pulsed field energy to ablate the heart tissue causing the problem. Researchers will track how well the procedure reduces arrhythmia burden and monitor for complications within the first week.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dual energy catheter system that delivers radiofrequency and pulsed field ablation to treat abnormal heart rhythms
What this could lead to
If successful, this could offer a more effective and safer way to treat ventricular arrhythmias, potentially reducing the need for repeat procedures.
What could go wrong
This is an early-stage workflow study with a small number of participants. The procedure carries risks such as heart damage, stroke, or bleeding, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Participant is planned for a catheter ablation procedure to ablate either: (a) Premature ventricular complexes (PVCs); (b) Sustained monomorphic ventricular tachycardia (VT), including sustained monomorphic ischemic ventricular tachycardia (SMIVT) or sustained monomorphic non-ischemic ventricular tachycardia (SMNIVT), with one or more documented spontaneous episodes of symptomatic sustained monomorphic ventricular tachycardia within 3 months that required device therapy (shock or anti-tachycardia pacing), external cardioversion, escalated antiarrhythmic therapy, and/or hospitalization. Documented episodes will be assessed by review of electrocardiographic data. 2. Age greater than or equal to 18 years 3. Willing and capable of providing consent 4. Able and willing to comply with all pre-, post-, and follow-up testing and requirements 5. For participants with sustained monomorphic ventricular tachycardia (SMIVT or SMNIVT): participant must have an implantable cardioverter defibrillator (ICD) already implanted before the ventricular tachycardia ablation procedure, or implantation must be planned during or soon after the ablation procedure, during the same hospital admission Exclusion criteria: 1. Incessant ventricular arrhythmia (VA) necessitating hemodynamic support prior to the ablation procedure 2. Polymorphic ventricular tachycardia, unstable ventricular tachycardia, or ventricular fibrillation (VF) 3. Idiopathic VTs 4. Suspected reversible cause of VA (example, electrolyte abnormalities, thyroid disease, drug induced arrhythmia) 5. VAs that are thought to be from channelopathies 6. Severely compromised left ventricular ejection fraction (LVEF) (less than \[\<\] 20 percentage \[%\]) 7. Uncontrolled heart failure or New York Heart Association (NYHA) Class IV 8. Pre-procedure stimulation protocol anticipated to be unsafe at the time of the screening visit (e.g., hemodynamically unstable participants, participants with ventricular fibrillation), per Site Investigator discretion 9. Previous Percutaneous Coronary Intervention (PCI) / Myocardial Infarction (MI) within the past 2 months 10. Unstable angina pectoris within the past 6 months. 11. Presence of intracardiac thrombus on pre-ablation imaging 12. Presence of a condition that precludes vascular access (such as inferior vena cava \[IVC\] filter in case of anterograde approach) 13. Epicardial mapping or ablation already anticipated or planned at the time of the screening visit (that is, pre-planned epicardial approach before index VA ablation per protocol) 14. History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran) 15. Contraindication to contrast agents. 16. Life expectancy \< 6 months, including advanced heart failure or terminal illness (at the discretion of the Investigator) 17. Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 6 months 18. Previous VA ablation within 6 months 19. Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the clinical investigation 20. Significant congenital anomaly or medical problem that in the opinion of the principal Investigator would preclude enrollment in the study 21. Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions For Use (IFU) 22. Ventriculotomy or atriotomy within the preceding 8 weeks 23. Presence of myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation 24. Prosthetic valves 25. Acute illness, active systemic infection, or sepsis 26. Current enrollment in an investigational study evaluating another device, biologic, or drug 27. Categorized as vulnerable population and requiring special treatment with respect to safeguards of well-being

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arrhythmias, cardiac are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AZ Sint-Jan Brugge

    RECRUITING

    Bruges, 8000, Belgium

  • AZORG campus Aalst Moorselbaan

    RECRUITING

    Aalst, 9300, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.